Kalkine has a fully transformed New Avatar.

BLINKLAB FPO

Healthcare AU BB1

0.475AUD
-0.005(1.04%)

Last update at 2025-07-25T06:10:00Z

Day Range

0.470.49
LowHigh

52 Week Range

0.200.59
LowHigh

Fundamentals

  • Previous Close 0.48
  • Market Cap60.08M
  • Volume27743
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.59656M
  • Revenue TTM0.19M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM -0.53501M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30
Income before tax -1.75327M -0.67638M -0.48515M
Minority interest - - -
Net income -1.75327M -0.67638M -0.48515M
Selling general administrative 1.51M 0.61M 0.46M
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation 0.08M 0.06M -
Ebit - - -
Ebitda - - -
Depreciation and amortization - - -
Non operating income net other - - -
Operating income -1.74874M -0.67506M -0.48315M
Other operating expenses - - -
Interest expense 0.00453M 0.00132M -
Tax provision 0.00000M 0.00000M 0.00000M
Interest income 0.00453M 0.00132M 0.00199M
Net interest income -0.00453M -0.00132M -
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense - - -
Total revenue 0.00000M 0.00000M 0.00000M
Total operating expenses - - -
Cost of revenue - - -
Total other income expense net 0.04M - -
Discontinued operations - - -
Net income from continuing ops -1.75327M -0.67638M -
Net income applicable to common shares -1.75327M -0.67638M -0.48515M
Preferred stock and other adjustments - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30
Total assets 6.87M 0.37M 0.91M
Intangible assets 0.35M 0.26M 0.21M
Earning assets - - -
Other current assets - - -
Total liab 0.39M 0.33M 0.19M
Total stockholder equity 6.48M 0.04M 0.72M
Deferred long term liab - - -
Other current liab - - -
Common stock - - 1.20M
Capital stock 9.11M 1.20M -
Retained earnings -2.91480M -1.16153M -0.48515M
Other liab - - -
Good will - - -
Other assets - - -
Cash 3.02M 0.05M 0.62M
Cash and equivalents - - -
Total current liabilities 0.27M 0.32M 0.18M
Current deferred revenue - - -
Net debt - - -
Short term debt - - 0.00000M
Short long term debt - - -
Short long term debt total - - -
Other stockholder equity - - -
Property plant equipment - - 0.08M
Total current assets 6.31M 0.05M 0.62M
Long term investments - - -
Net tangible assets - - -
Short term investments 3.00M - -
Net receivables - 0.00427M 0.00603M
Long term debt - - -
Inventory - - -
Accounts payable 0.13M 0.31M -
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other - - -
Deferred long term asset charges - - -
Non current assets total 0.56M 0.32M -
Capital lease obligations 0.17M 0.02M -
Long term debt total - - 0.02M
Breakdown 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30
Investments -3.14396M -0.08307M -
Change to liabilities - - -
Total cashflows from investing activities -3.14396M -0.08307M -0.26486M
Net borrowings - - -
Total cash from financing activities 7.87M -0.01420M 1.19M
Change to operating activities - - -
Net income -1.75327M -0.67638M -
Change in cash 2.97M -0.56686M 0.62M
Begin period cash flow 0.05M 0.62M -
End period cash flow 3.02M 0.05M -
Total cash from operating activities -1.75287M -0.47334M -0.30333M
Issuance of capital stock 8.41M - -
Depreciation - - -
Other cashflows from investing activities -3.00000M - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock 8.41M 0.00000M 1.20M
Other cashflows from financing activities -0.49584M - -
Change to netincome - - -
Capital expenditures 0.14M 0.08M 0.26M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 0.03M -0.00132M -0.00199M
Stock based compensation - - -
Other non cash items - - -
Free cash flow -1.89683M -0.55641M -

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
BB1
BLINKLAB FPO
-0.005 1.04% 0.47 - - 308.32 13.18
PME
Pro Medicus Ltd
0.93 0.29% 320.85 345.00 200.00 182.77 150.37 180.15 236.69
CGS
CogState Ltd
0.05 2.79% 1.84 30.25 19.92 6.53 4.50 3.45 12.72
ONE
Oneview Healthcare PLC
0.03 10.00% 0.28 - - 19.52 8.48 10.07 -3.5247
ALC
Alcidion Group Ltd
-0.005 4.00% 0.12 - 125.00 4.90 1.97 4.53 53.70

Reports Covered

Stock Research & News

Profile

BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-neurobehavioral testing. The company's smartphone-based application serves as a device for conducting neurobehavioral evaluations. Its application also enables remote and rapid testing to aid research on neurodevelopmental and neurodegenerative conditions such as schizophrenia, autism, attention deficit hyperactivity disorder (ADHD), and various forms of dementia. The company was incorporated in 2021 and is based in Sydney, Australia.

BLINKLAB FPO

126-130 Phillip Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Dr. Hendrikus Johannes Boele M.D., Ph.D. Founder & CEO NA
Mr. Cornelis Pieter Boele Founder & Chief Technology Officer NA
Dr. Sebastiaan K.E Koekkoek Founder & Chief Scientific Officer NA
Dr. Anton Uvarov BioChem, MBA, MedGen, Ph.D. Executive Director NA
Ms. Kamille Dietrich Company Secretary NA
Mr. Christopher Achurch Company Secretary NA
Dr. Hendrikus Johannes Boele M.D., Ph.D. Founder & CEO NA
Mr. Cornelis Pieter Boele Founder & Chief Technology Officer NA
Dr. Sebastiaan K.E Koekkoek Founder & Chief Scientific Officer NA
Dr. Anton Uvarov BioChem, MBA, MedGen, Ph.D. Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.